Compare GIGM & NCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GIGM | NCEL |
|---|---|---|
| Founded | 1998 | 2008 |
| Country | Taiwan | Switzerland |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.8M | 20.7M |
| IPO Year | 2000 | N/A |
| Metric | GIGM | NCEL |
|---|---|---|
| Price | $1.46 | $2.53 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 4.0K | ★ 90.9K |
| Earning Date | 10-30-2025 | 12-01-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,397,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 10.11 | N/A |
| 52 Week Low | $1.38 | $2.48 |
| 52 Week High | $1.89 | $7.64 |
| Indicator | GIGM | NCEL |
|---|---|---|
| Relative Strength Index (RSI) | 40.05 | N/A |
| Support Level | $1.50 | N/A |
| Resistance Level | $1.56 | N/A |
| Average True Range (ATR) | 0.05 | 0.00 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 13.33 | 0.00 |
GigaMedia Ltd is a diversified provider of digital entertainment services. Its only segment and principal business is digital entertainment service business, which operates a portfolio of digital entertainment products, targeting digital entertainment service users across Asia. It operates digital entertainment business in Taiwan, Hong Kong and Macau through FunTown.
NewcelX Ltd is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company's integrated platform combines advanced stem-cell technologies and neuroscience expertise to deliver scalable, regenerative treatments targeting conditions such as Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes. It has research and development operations in Ness Ziona, Israel.